Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Sentiment | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|---|
| ONC | BEONE MEDICINES LTD | $40.31B | 1,438,553,263 | 2.29% | 32.11% | Net Selling | Net Selling | ||
| CORT | CORCEPT THERAPEUTICS INC | $7.90B | 105,188,217 | 28.38% | 71.62% | Net Selling | Net Selling | ||
| NVO | NOVO NORDISK A S | $211.29B | 4,443,500,000 | 6.66% | 0.00% | ||||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $61.08B | 132,113,818 | 82.23% | 17.77% | Net Selling | Net Selling | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $151.19M | 80,421,181 | 9.25% | 90.75% | Net Buying | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $546.09M | 56,297,535 | 70.63% | 22.18% | Net Selling | Net Buying | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $3.13B | 75,795,759 | 51.88% | 9.40% | Net Selling | Net Selling | ||
| LGND | LIGAND PHARMACEUTICALS INC | $4.08B | 19,681,720 | 28.34% | 71.66% | Net Selling | Net Selling | ||
| GMAB | GENMAB A | $19.47B | 64,206,349 | 95.87% | 0.00% | ||||
| ARGX | ARGENX SE | $56.06B | 61,034,202 | 49.61% | 0.00% | ||||
| VCEL | VERICEL CORP | $1.97B | 50,574,026 | 91.17% | 8.83% | Net Selling | Net Selling | ||
| RPRX | ROYALTY PHARMA PLC | $22.78B | 577,238,107 | 56.56% | 17.46% | Net Selling | Net Buying | ||
| KRYS | KRYSTAL BIOTECH INC | $5.94B | 28,997,519 | 78.83% | 21.17% | Net Selling | |||
| TECH | BIO-TECHNE CORP | $9.06B | 155,812,701 | 97.61% | 2.39% | Net Buying | Net Selling | ||
| CRMD | CORMEDIX INC | $793.80M | 78,789,045 | 51.97% | 8.71% | Net Selling | Net Buying | ||
| HALO | HALOZYME THERAPEUTICS INC | $8.24B | 117,597,000 | 77.22% | 22.78% | Net Selling | Net Selling | ||
| MDXG | MIMEDX GROUP INC | $995.25M | 148,102,159 | 46.40% | 53.60% | Net Buying | Net Selling | ||
| GYRE | GYRE THERAPEUTICS INC | $738.88M | 96,333,157 | 1.87% | 98.13% | Net Buying | |||
| VCYT | VERACYTE INC | $3.06B | 79,049,173 | 67.51% | 32.49% | Net Selling | Net Selling | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.40B | 192,114,344 | 92.42% | 1.74% | Net Selling | Net Selling | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $110.50B | 253,718,831 | 90.57% | 1.52% | Net Selling | Net Selling | ||
| INCY | INCYTE CORP | $20.40B | 196,322,703 | 77.28% | 22.72% | Net Selling | Net Selling | ||
| ADMA | ADMA BIOLOGICS INC | $3.73B | 237,997,765 | 79.42% | 20.58% | Net Selling | Net Selling | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.96B | 57,596,358 | 75.91% | 24.09% | Net Selling | Net Selling | ||
| INVA | INNOVIVA INC | $1.64B | 74,769,062 | 60.24% | 39.76% | Net Selling | Net Buying | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $2.04B | 131,840,559 | 48.30% | 12.61% | Net Buying | |||
| EXEL | EXELIXIS INC | $11.43B | 268,112,157 | 92.51% | 5.20% | Net Selling | Net Selling | ||
| MNKD | MANNKIND CORP | $1.55B | 307,070,281 | 35.30% | 64.70% | Net Selling | Net Selling | ||
| REGN | REGENERON PHARMACEUTICALS INC | $76.23B | 105,099,464 | 68.11% | 31.89% | Net Selling | Net Buying | ||
| UTHR | UNITED THERAPEUTICS CORP | $20.52B | 43,056,599 | 86.53% | 13.47% | Net Selling | Net Selling | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.79B | 122,912,387 | 82.91% | 15.87% | Net Buying | Net Buying |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.